312 related articles for article (PubMed ID: 23252692)
1. Abuse-deterrent and tamper-resistant opioids: how valuable are novel formulations in thwarting non-medical use?
Lourenço LM; Matthews M; Jamison RN
Expert Opin Drug Deliv; 2013 Feb; 10(2):229-40. PubMed ID: 23252692
[TBL] [Abstract][Full Text] [Related]
2. Tamper-resistant opioid formulations in the treatment of acute pain.
Passik SD
Adv Ther; 2014 Mar; 31(3):264-75. PubMed ID: 24526323
[TBL] [Abstract][Full Text] [Related]
3. Abuse-deterrent formulations of prescription opioid analgesics in the management of chronic noncancer pain.
Hale ME; Moe D; Bond M; Gasior M; Malamut R
Pain Manag; 2016 Oct; 6(5):497-508. PubMed ID: 27050830
[TBL] [Abstract][Full Text] [Related]
4. Abuse-deterrent and tamper-resistant opioid formulations: what is their role in addressing prescription opioid abuse?
Schneider JP; Matthews M; Jamison RN
CNS Drugs; 2010 Oct; 24(10):805-10. PubMed ID: 20839893
[TBL] [Abstract][Full Text] [Related]
5. Will abuse-deterrent formulations of opioid analgesics be successful in achieving their purpose?
Bannwarth B
Drugs; 2012 Sep; 72(13):1713-23. PubMed ID: 22931520
[TBL] [Abstract][Full Text] [Related]
6. Routes of abuse of prescription opioid analgesics: a review and assessment of the potential impact of abuse-deterrent formulations.
Gasior M; Bond M; Malamut R
Postgrad Med; 2016 Jan; 128(1):85-96. PubMed ID: 26566680
[TBL] [Abstract][Full Text] [Related]
7. Opioids with abuse-deterrent properties: A regulatory and technological overview.
Haddox JD
J Opioid Manag; 2017; 13(6):397-413. PubMed ID: 29308587
[TBL] [Abstract][Full Text] [Related]
8. Assessing the impact of abuse-deterrent opioids (ADOs): identifying epidemiologic factors related to new entrants with low population exposure.
Roland CL; Setnik B; Brown DA
Postgrad Med; 2017 Jan; 129(1):12-21. PubMed ID: 27960575
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of Abuse-Deterrent or Tamper-Resistant Opioid Formulations on Overall Health Care Expenditures in a State Medicaid Program.
Keast SL; Owora A; Nesser N; Farmer K
J Manag Care Spec Pharm; 2016 Apr; 22(4):347-56. PubMed ID: 27023688
[TBL] [Abstract][Full Text] [Related]
10. Current Impact and Application of Abuse-Deterrent Opioid Formulations in Clinical Practice.
Lee YH; Brown DL; Chen HY
Pain Physician; 2017 Nov; 20(7):E1003-E1023. PubMed ID: 29149148
[TBL] [Abstract][Full Text] [Related]
11. Impact of Abuse Deterrent Formulations of Opioids in Patients With Chronic Pain in the United States: A Cost-Effectiveness Model.
Kumar VM; Agboola F; Synnott PG; Segel C; Webb M; Ollendorf DA; Banken R; Chapman RH
Value Health; 2019 Apr; 22(4):416-422. PubMed ID: 30975392
[TBL] [Abstract][Full Text] [Related]
12. Abuse-deterrent formulations: part 2: commercial products and proprietary technologies.
Mastropietro DJ; Omidian H
Expert Opin Pharmacother; 2015 Feb; 16(3):305-23. PubMed ID: 25421961
[TBL] [Abstract][Full Text] [Related]
13. Abuse-deterrent opioids: an update on current approaches and considerations.
Pergolizzi JV; Raffa RB; Taylor R; Vacalis S
Curr Med Res Opin; 2018 Apr; 34(4):711-723. PubMed ID: 29262730
[TBL] [Abstract][Full Text] [Related]
14. Current and future development of extended-release, abuse-deterrent opioid formulations in the United States.
Webster LR; Markman J; Cone EJ; Niebler G
Postgrad Med; 2017 Jan; 129(1):102-110. PubMed ID: 27915497
[TBL] [Abstract][Full Text] [Related]
15. Drug Formulation Advances in Extended-Release Medications for Pain Control.
Jones MR; Carney MJ; Kaye RJ; Prabhakar A; Kaye AD
Curr Pain Headache Rep; 2016 Jun; 20(6):36. PubMed ID: 27084375
[TBL] [Abstract][Full Text] [Related]
16. Evaluating the potential impact of a reformulated version of oxycodone upon tampering, non-adherence and diversion of opioids: the National Opioid Medications Abuse Deterrence (NOMAD) study protocol.
Degenhardt L; Larance B; Bruno R; Lintzeris N; Ali R; Farrell M
Addiction; 2015 Feb; 110(2):226-37. PubMed ID: 25358480
[TBL] [Abstract][Full Text] [Related]
17. Update on abuse-resistant and abuse-deterrent approaches to opioid formulations.
Webster L
Pain Med; 2009 Jul; 10 Suppl 2():S124-33. PubMed ID: 19691683
[TBL] [Abstract][Full Text] [Related]
18. Reducing extramedical use and harms of pharmaceutical opioids: the potential role of abuse-deterrent formulations.
Degenhardt L; Larance B; Peacock A; Farrell M
Lancet Psychiatry; 2015 Nov; 2(11):957-9. PubMed ID: 26544739
[No Abstract] [Full Text] [Related]
19. The effect of a potentially tamper-resistant oxycodone formulation on opioid use and harm: main findings of the National Opioid Medications Abuse Deterrence (NOMAD) study.
Larance B; Dobbins T; Peacock A; Ali R; Bruno R; Lintzeris N; Farrell M; Degenhardt L
Lancet Psychiatry; 2018 Feb; 5(2):155-166. PubMed ID: 29336948
[TBL] [Abstract][Full Text] [Related]
20. Physicians' beliefs and likelihood of prescribing opioid tamper-resistant formulations for chronic noncancer pain patients.
Turk DC; Dansie EJ; Wilson HD; Moskovitz B; Kim M
Pain Med; 2014 Apr; 15(4):625-36. PubMed ID: 24612185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
